

Neuro-Oncology 18:iii18–iii23, 2016.
doi:10.1093/neuonc/nov068.12

NEURO-ONCOLOGY

Abstracts

CR-12. INTRACYSTIC INTERFERON-ALPHA IN PAEDIATRIC CRANIOPHARYNGIOMA PATIENTS: AN INTERNATIONAL MULTI-CENTRE ASSESSMENT ON BEHALF OF SIOP-E AND ISPN
J.P. Kilday^{1,2}, L. Massimi³, M. Caldarelli³, Y.Y. Lee⁴, H.H. Chen⁴, M.L. Yiang⁴, J. Parkes⁵, T. Naiker⁵, M. van Veelen⁶, E. Michiels⁶, B. Pettorini⁷, C. Mallucci⁷, L. Meijer⁸, C. Dorfer⁹, T. Czech⁹, M. Diezi¹⁰, N. van Schouten¹¹, S. Holm¹², B. Gustavsson¹², M. Benesch¹³, A. Hoffman¹⁴, H. Muller¹⁴, G. Escherich¹⁵, J. Flitsch¹⁵, S. Rutkowski¹⁵, M. Grotzer¹⁶, H.A. Spoudeas¹⁷, M. Capra¹⁸, R. Jimenez-Guerra¹⁹, P. MacDonald²⁰, D.L. Johnston²¹, R. Dvir²², S. Constantini²², M.F. Kuo²³, S.H. Yang²³, and U. Bartels²⁴; ¹Royal Manchester Children's Hospital NHS Foundation Trust, Manchester, UK; ²CBTRN/Institute of Cancer Sciences, University of Manchester, Manchester, UK; ³A. Gemelli Hospital, Rome, Italy; ⁴Taipei Veterans General Hospital, Taipei, Taiwan; ⁵Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa; ⁶Sophia Children's Hospital, Erasmus MC, Rotterdam, The Netherlands; ⁷Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK; ⁸Beatrix Children's Hospital, University MC, Groningen, The Netherlands; ⁹Dept. of Neurosurgery, Medical University of Vienna, AKH, Vienna, Austria; ¹⁰Paediatric Haemato-Oncology Unit, University Hospital Lausanne, Lausanne, Switzerland; ¹¹Emma Children's Hospital, Amsterdam MC, Amsterdam, The Netherlands; ¹²Karolinska University Hospital, Stockholm, Sweden; ¹³Medical University of Graz, Graz, Austria; ¹⁴Department of Paediatrics, Klinikum Oldenburg, Medical Campus University, Oldenburg, Germany; ¹⁵University Hospital of Hamburg-Eppendorf, Hamburg, Germany; ¹⁶University Children's Hospital Zurich, Zurich, Switzerland; ¹⁷Department of Paediatric Neuroendocrinology, Great Ormond Street Hospital NHS Foundation Trust, London, UK; ¹⁸Our

Lady's Children's Hospital, Crumlin, Ireland; ¹⁹Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City, Mexico; ²⁰Winnipeg Children's Hospital, Winnipeg, MB, Canada; ²¹Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; ²²Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; ²³Department of Neurosurgery, National Taiwan University Hospital, Taipei, Taiwan; ²⁴The Hospital for Sick Children, Toronto, ON, Canada

BACKGROUND: Craniopharyngiomas are frequently diagnosed hypothalamo-pituitary lesions in children where they present as predominantly cystic lesions, lined by a secretory squamous epithelium. Morbidity associated with current therapeutic regimens has focussed attention towards intracystic treatments as a mode of delivery, hypothesised to cause fewer clinical consequences. However, the true efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centres in using intracystic interferon-alpha. **METHODS:** All SIOP Europe and ISPN centres were contacted to submit an anonymised datasheet capturing paediatric patients in their care with a cystic craniopharyngioma that had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events and outcomes were captured. Progression was clinical or radiological (cyst re-accumulation, novel cysts, or solid growth). **RESULTS:** Fifty-five children (median age of 6.5 years) from over 20 international centres were identified. Median follow-up was 5 years (0.3–17.7 years; median 2.7 years post interferon). Lesions were either cystic (n = 21; 38%) or cystic/solid (n = 34; 62%). Progression had been treated in 43 (78%) patients prior to interferon use. Progression was delayed by interferon when compared to the preceding therapy for such patients (p = 0.005), especially in cystic cases (p = 0.0001). Progression post interferon occurred in 40 patients (median 14 months; 0–8 years). Few significant attributable side effects were reported. **CONCLUSION:** Interferon-alpha appears to delay disease progression in paediatric craniopharyngioma and has a favourable toxicity profile compared to other modalities, both important factors in this developing age group. Prospective, randomised international clinical trial assessment is warranted.